STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] Qualigen Therapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

AIxCrypto Holdings, Inc., formerly operating under the Nasdaq ticker QLGN, reported that it has launched a new corporate name and trading symbol “AIXC”. The company marked this rebranding with a presentation at Nasdaq headquarters, where it highlighted the new name and elements of an updated business plan focused on its AI and crypto-related strategy.

The company also issued a press release on November 20, 2025, announcing the rebranding and updated business plan, which is included as an exhibit to this report. A video link to the Nasdaq presentation was provided for investors and the public to review the company’s new positioning and strategic direction.

Positive
  • None.
Negative
  • None.
false 0001460702 0001460702 2025-11-20 2025-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) November 20, 2025

 

AIxCrypto Holdings, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-37428   26-3474527

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

5857 Owens Avenue, Suite 300, Carlsbad, California 92008
(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code (760) 452-8111

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock (par value $0.001 per share)   QLGN   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

 

Item 7.01. Regulation FD

 

On Thursday, November 20, 2025, AIxCrypto Holdings, Inc. (the “Company”) presented at Nasdaq headquarters to launch its new name of AIxCrypto Holdings, Inc. and new trading symbol “AIXC”, as well as certain aspects of the Company’s new business plan.

 

A link to the presentation may be found at: https://youtu.be/WEWHZyR49MA

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.”

 

Item 8.01. Other Events.

 

Also on November 20, 2025, the Company issued a press release announcing the rebranding of the Company and its updated business plan. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 8.01 by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Exhibit Description
99.1   Press Release dated November 20, 2025
104   Cover Page Interactive Data File (embedded within the Inline XBRL Document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 20, 2025 AIxCRYPTO HOLDINGS, INC.
   
  By: /s/ Kevin A. Richardson II
  Name: Kevin A. Richardson II
  Title: Co-Chief Executive Officer

 

 

 

FAQ

What did AIxCrypto Holdings, Inc. (QLGN) announce in this 8-K filing?

The company announced a rebranding to AIxCrypto Holdings, Inc., the launch of a new Nasdaq trading symbol AIXC, and highlighted aspects of an updated business plan.

What is the new trading symbol for AIxCrypto Holdings, Inc.?

The company stated that its new Nasdaq trading symbol is “AIXC”, replacing its prior symbol QLGN.

Did AIxCrypto Holdings, Inc. present its new business plan publicly?

Yes. On November 20, 2025, the company presented at Nasdaq headquarters, discussing its new name, new ticker AIXC, and certain aspects of its updated business plan.

Is there a way to view AIxCrypto Holdings, Inc.’s Nasdaq presentation?

Yes. The company provided a link to a video of the presentation at https://youtu.be/WEWHZyR49MA.

What additional disclosure did AIxCrypto Holdings, Inc. provide with this 8-K?

The company issued a press release announcing the rebranding and updated business plan, which is attached as Exhibit 99.1 and incorporated by reference into the filing.

Is the Nasdaq presentation information considered filed for liability purposes?

No. The company stated that, under General Instruction B.2, the information in Item 7.01 is not deemed “filed” for purposes of Section 18 of the Exchange Act.
Qualigen Therapeutics Inc

NASDAQ:QLGN

QLGN Rankings

QLGN Latest News

QLGN Latest SEC Filings

QLGN Stock Data

6.53M
2.62M
2.17%
0.72%
2.03%
Biotechnology
Pharmaceutical Preparations
Link
United States
CALIFORNIA